Version June 2024
| Surgery | Radiotherapy | Octreotide, lanreotide | Cabergoline | Pegvisomant | ||
| Microadenoma | Macroadenoma | |||||
| Normal IGF-1 | 80-90% | 40% | 50% at 10 years | 50% | 40% | 95% |
| Adenoma shrinkage | 95% | 70% | 95% | 50% | No data | Not expected |
| Advantages | Potential cure reduction | Rapid size reduction | Oral administration | |||
| Disadvantages | Recurrence: 5-10% | Regrowth of adenoma | Slow | Injection | Injection | |
| Complications | ||||||
| Hypopituitarism | Rare | 15% | 50% at 10 years | None | None | None |
| Other | Diabetes insipidus, 5% | Diabetes insipidus, 10% | Neurological deficits | GI symptoms, gallstones | Nausea, lassitude | Elevated liver enzymes |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
